Oversold, OCGN is gaining momentum.
According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN also exhibited 70% efficacy against asymptomatic cases, which could be vital in thwarting asymptomatic spread.”
The stock is up about 17% in pre-market to $11.25 and running.
This is just one of the opportunities we find quite often inside Extreme Option Profits.